Bal Pharma
: BALPHARMA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bal Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bal Pharma is a fully integrated pharmaceutical company engaged in the manufacturing and sale of bulk drugs, prescription medicines, generics, and Ayurvedic products. The company maintains a strong focus on therapeutic areas including anti-diabetes, cardiology, and dermatology.
Business Model
The company generates revenue through the production and export of pharmaceutical formulations and active pharmaceutical ingredients. It leverages its position as a major producer of Gliclazide to serve both domestic and international markets.
- Core Specialisation:Gliclazide production
Growth Outlook
Growth is driven by the company's established presence in the anti-diabetes segment and its ongoing export operations. Continued focus on diverse therapeutic areas supports its market expansion strategy.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could disrupt operations.
- Price Controls. Government-mandated price caps on essential medicines in India may exert pressure on profit margins.
- Raw Material Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can impact the overall cost of production.
- Competitive Market. The pharmaceutical sector is highly fragmented, leading to intense price competition from both domestic and international generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Bal Pharma and 5,000+ companies — free.
Key Metrics
P/E
21.9x
Q4 FY26 · consolidated
EV/EBITDA
7.7x
Q4 FY26 · consolidated
NET PROFIT MARGIN
4.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
1.9x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bal PharmaBALPHARMA | ₹135 Cr | 21.41 | 8.64 | — | 10.9% | 8.0% | 19.2% | -2.3% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Bal Pharma
: BALPHARMA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bal Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bal Pharma is a fully integrated pharmaceutical company engaged in the manufacturing and sale of bulk drugs, prescription medicines, generics, and Ayurvedic products. The company maintains a strong focus on therapeutic areas including anti-diabetes, cardiology, and dermatology.
Business Model
The company generates revenue through the production and export of pharmaceutical formulations and active pharmaceutical ingredients. It leverages its position as a major producer of Gliclazide to serve both domestic and international markets.
- Core Specialisation:Gliclazide production
Growth Outlook
Growth is driven by the company's established presence in the anti-diabetes segment and its ongoing export operations. Continued focus on diverse therapeutic areas supports its market expansion strategy.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could disrupt operations.
- Price Controls. Government-mandated price caps on essential medicines in India may exert pressure on profit margins.
- Raw Material Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can impact the overall cost of production.
- Competitive Market. The pharmaceutical sector is highly fragmented, leading to intense price competition from both domestic and international generic manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Bal Pharma and 5,000+ companies — free.
Key Metrics
P/E
21.9x
Q4 FY26 · consolidated
EV/EBITDA
7.7x
Q4 FY26 · consolidated
NET PROFIT MARGIN
4.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
1.9x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26